| Old Articles: <Older 7961-7970 Newer> |
|---|
 |
Pharmaceutical Executive
October 1, 2011
Jill Wechsler |
At the Helm of Industry As the lead FDA official overseeing the testing and approval of new drugs and biotech therapies for some 20 years, Dr. Janet Woodcock has built a robust and modern drug regulatory system.   |
Pharmaceutical Executive
October 1, 2011 |
Arming up for the Digital Revolution As a longtime advocate of new approaches to meeting customer needs in pharma, Martin Wygod sees the biggest change as the coming growth of digital platforms as the principal source of information and communication in healthcare. |
Pharmaceutical Executive
October 1, 2011
William Looney |
Curative Powers of Collaboration Napoleone Ferrara's career in medicine is an illustration of the maxim that stretching the boundaries of science is a leap in the dark. |
Pharmaceutical Executive
October 1, 2011
William Looney |
Minting the Database Dennis Gillings is proof positive that in the pharma industry, some of the best minds in business originate in academia. |
Pharmaceutical Executive
October 1, 2011
David Balekdjian |
In Establishing the Evidence Base, He Made Science Count Robert Seidman leveraged his role as the insurer group WellPoint's first Chief Pharmacy Officer to drive many important changes in the institutional relationship between Big Pharma and its now equally big customers. |
Pharmaceutical Executive
October 1, 2011
William Looney |
The East is Up Candan Karabagli is CEO of Turkey's largest pharmaceutical company, Abdi Ibrahim, where she is responsible for consolidating the company's lead position in Turkey through more in-house R&D and licensing deals with innovative companies while building a stronger regional footprint. |
Pharmaceutical Executive
October 1, 2011
William Looney |
Productivity, Reputation are Keys to Global Leadership As CEO of Japan's largest pharmaceutical company and chair of Keizai Doyukai representing Japan's corporate business community, Yasuchika Hasegawa has the platform to pursue a two-pronged agenda that artfully fuses global and domestic priorities. |
Pharmaceutical Executive
October 1, 2011
Ernst R. Berndt |
Academia Sweet Spot: Where Policy and Business Converge Economics Professor Henry Grabowski's scholarly contributions have had enormous impact outside academy. Much legislation affecting pharmaceuticals, vaccines, and biotechnology products has been enacted based on his insights. |
Pharmaceutical Executive
October 1, 2011
Jill Wechsler |
"Representing" Healthcare to the Fullest Since coming to Congress about 35 years ago, Henry Waxman, Congressional Representative from Los Angeles, California, has been pivotal in shaping legislation on health and drug regulatory issues. |
Pharmaceutical Executive
October 1, 2011
William Looney |
Getting to No. 1 -- and Staying There Former Merck CEO P. Roy Vagelos led the company during its peak years from 1985 to 1994. |
| <Older 7961-7970 Newer> Return to current articles. |
